1. Market Research
  2. > Infantile Hemangiomas - Pipeline Review, H2 2013

Infantile Hemangiomas - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 32 pages

Infantile Hemangiomas - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Infantile Hemangiomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Infantile Hemangiomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infantile Hemangiomas. Infantile Hemangiomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Infantile Hemangiomas.
- A review of the Infantile Hemangiomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Infantile Hemangiomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Infantile Hemangiomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Infantile Hemangiomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Infantile Hemangiomas - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Infantile Hemangiomas Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Infantile Hemangiomas 7
Infantile Hemangiomas Therapeutics under Development by Companies 9
Infantile Hemangiomas Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Infantile Hemangiomas Therapeutics - Products under Development by Companies 14
Infantile Hemangiomas Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Infantile Hemangiomas Therapeutics Development 16
Laboratoires Pierre Fabre SA 16
InfectoPharm Arzneimittel und Consilium GmbH 17
Infantile Hemangiomas - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
nadolol - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
propranolol hydrochloride - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
propranolol hydrochloride - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
timolol maleate - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
timolol maleate - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
timolol maleate - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
propranolol hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Infantile Hemangiomas Therapeutics - Drug Profile Updates 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32



List of Tables

Number of Products Under Development for Infantile Hemangiomas, H2 2013 7
Products under Development for Infantile Hemangiomas - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Laboratoires Pierre Fabre SA, H2 2013 16
InfectoPharm Arzneimittel und Consilium GmbH, H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 22
Infantile Hemangiomas Therapeutics - Drug Profile Updates 30



List of Figures

Number of Products under Development for Infantile Hemangiomas, H2 2013 7
Products under Development for Infantile Hemangiomas - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 18
Assessment by Route of Administration, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Molecule Type, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 22



Companies Mentioned

Laboratoires Pierre Fabre SA
InfectoPharm Arzneimittel und Consilium GmbH

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.